Dr Matthew Hind is a consultant respiratory physician at Royal Brompton Hospital where he treats private and NHS patients.
He studied medicine at King’s College London and completed postgraduate training in respiratory medicine at a number of London hospitals - Royal Free, Royal Brompton, Hammersmith, St Mary's and St George's hospitals.
He completed a PhD in regenerative biology funded by the Wellcome Trust, discovering that damaged lungs can regenerate in response to a particular molecular signal.
For this work, he received a prestigious European Respiratory Society COPD award for 'outstanding contribution to COPD research in Europe' and a 'Young Investigator' award from the British Thoracic Society.
Dr Matthew Hind specialises in all adult respiratory medicine and sleep disorders and is one of three full-time clinicians on the lung failure team at Royal Brompton Hospital.
He has particular expertise in:
smoking-related lung disease
continuous positive airway pressure (CPAP).
He has established and led multi-disciplinary medical teams working on complex clinical cases both in the UK and internationally.
Dr Hind is the lead for stem and regenerative therapies at the advanced lung disease unit. This is a partnership between Royal Brompton Hospital and Imperial College London, funded by the National Institute for Health Research (NIHR).
Dr Matthew Hind believes the cellular and molecular cues which control development may be used to induce lung regenerative programmes conserved across species.
He has used derivatives of vitamin A including retinoic acid, identified as essential for regeneration in a wide variety of animals and organ systems, in human lung models of increasing complexity including primary cells, lung slices and ex vivo lung perfusion models of lung injuries.
Dr Hind has established a lung development and regeneration laboratory at the National Heart and Lung Institute (NHLI). His group are actively researching the molecular signals that switch on lung repair pathways to develop new treatments for patients with lung disease.
To understand the biology of this process, the group have developed novel human tissue models and are applying genomics to study the molecular and cellular biology of lung regeneration. The development of new human lung models has been recognised with an NHS innovations award.
Dr Matthew Hind has published many articles on the basic science of lung development and regeneration, clinical respiratory medicine and novel treatments for patients with lung disease.
Dr Matthew Hind supervises and examines postgraduate PhD students at Imperial College London, is a clinical examiner for the Royal College of Physicians and is an honorary senior lecturer at the NHLI.
He is also an honorary research fellow at the Medical Research Council Centre for Developmental Neurobiology at King's College London.